<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Feb. 4, 2020 (HealthDay News) — Two modeling studies show how cervical cancer could be eliminated and mortality could be reduced, according to two studies published online Jan. 30 in The Lancet<\/i>.<\/p>\n
Marc Brisson, Ph.D., from Laval University in Quebec City, and colleagues examined the projected reductions in cervical cancer incidence over time in 78 low-income and lower middle-income countries (LMICs) for girls-only human papillomavirus vaccination (at age 9 years) and girls-only vaccination and once- or twice-lifetime screening. The researchers found that the predicted reduction in median age-standardized cervical cancer incidence was from 19.8 to 2.1 cases per 100,000 women-years (89.4 percent) with girls-only HPV vaccination, with 61 million cases averted during the next century. The incidence was further reduced to 0.7 cases per 100,000 women-years by adding twice-lifetime screening (96.7 percent reduction), and an extra 12.1 million cases would be averted. Depending on the threshold and region, elimination could occur between 2059 and 2102.<\/p>\n
Karen Canfell, D.Phil., from the Cancer Council New South Wales in Sydney, and colleagues estimated the reductions in age-standardized mortality in 78 LMICs for girls-only vaccination and girls-only vaccination plus once- or twice-lifetime screening and cancer treatment scale-up. The researchers found that by 2030, vaccination alone would have a minimal impact versus the status quo, leading to a 0.1 percent reduction in mortality; mortality would be reduced by 34.2 percent by the addition of twice-lifetime screening and cancer treatment, averting 300,000 deaths by 2030. By 2120, vaccination alone would reduce mortality by 89.5 percent; additional scaling-up screening and cancer treatment would reduce mortality by 97.9 or 98.6 percent with once- or twice-lifetime screening, respectively.<\/p>\n
“Considerable progress can be made in reducing the intolerable and preventable global burden of cervical cancer,” write the authors of an accompanying editorial.<\/p>\n
Two authors from both studies disclosed financial ties to the biopharmaceutical industry.<\/p>\n
Abstract\/Full Text – Brisson<\/a><\/p>\n Abstract\/Full Text – Canfell<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n